Peptide Side Effects, Organized by What Actually Causes Them.
“Peptide side effects” isn’t one list, it’s several genuinely different risk patterns depending on mechanism class. Here they are, sorted by class, each one sourced to a real trial, meta-analysis, or FDA document, not a vendor’s disclaimer page.
Reviewed by the PepGuard team · Last reviewed Jul 28, 2026
- GLP-1/amylin-class peptides carry a quantified injection-site-reaction risk: a 2026 meta-analysis of 14 trials found a 3.55x risk ratio versus comparators.
- GH-releasing peptides have documented cardiovascular signals, including a fatality in the only large CJC-1295 trial ever run.
- Manufacturing quality, aggregation and impurities, is a recognized, FDA-documented immunogenicity risk that applies to any unregulated compound, regardless of its own trial data.
- Some compounds, like KPV, have zero human data at all, a distinct risk category of its own.
Photo: Vitaly Gariev / UnsplashGI effects: the GLP-1 and amylin class.
Gastrointestinal effects, nausea, diarrhoea, vomiting, constipation, are the single most consistently reported side effect across GLP-1 and amylin-class peptides. In a Phase 2 cagrilintide trial, GI adverse events occurred in 41-63% of treatment groups versus 32% with placebo. In the larger REDEFINE 1 trial of the cagrilintide-semaglutide combination, 79.6% of the treatment group reported a GI adverse event versus 39.9% with placebo. These are real, trial-reported rates, not an estimate, and they scale up with dose and with combining compounds.
Injection-site and dermatologic reactions.
A 2026 meta-analysis pooled 14 randomized controlled trials (4,861 patients, 396 injection-site reaction events) and found GLP-1 receptor agonists carried more than triple the injection-site reaction risk of comparators, a risk ratio of 3.55 (95% confidence interval, 2.35-5.36). The same study ran a disproportionality analysis of FDA adverse-event data and flagged exenatide and dulaglutide specifically for injection-site haemorrhage. General dermatologic events, by contrast, were infrequent and not significantly elevated. This is a real, quantified number, one of the few in this entire space, not a category most guides mention at all.
Cardiovascular signals: the GH-releasing class.
CJC-1295’s only large human trial, a Phase 2 study of 192 participants with HIV-associated visceral obesity, was halted in 2006 after a participant died of a myocardial infarction hours after an injection. That’s a documented, isolated event, not proof the compound caused it, since causality was never established conclusively, but it’s the most serious safety signal attached to any peptide covered on this site.
GHRP-2’s own FDA bulk-substances review separately states the agency is “aware of reports of serious adverse events in patients who received GHRP-2, including increased insulin requirement to maintain the blood glucose level, death of critically ill study subjects, infection and pancreatitis,” while explicitly noting causality has not been established. Two separate compounds, two separate documented cardiovascular-adjacent signals, both with the same honest caveat: documented, not proven causal.
Immunogenicity: the risk that applies across the board.
Separate from any single compound’s own trial data, the FDA’s guidance on immunogenicity assessment for therapeutic protein products, which explicitly extends its principles to peptides, identifies product aggregates and manufacturing impurities as a recognized driver of unwanted immune responses, a relationship the agency notes has been documented for over half a century. An unregulated research vial has no requirement to control for either. This risk doesn’t show up in any individual compound’s trial data because it’s a manufacturing-quality problem, not a pharmacological one, covered in more depth in Are Peptides Safe?.
The compounds with zero data at all.
Not every peptide has a documented side-effect profile to report, and that absence is its own finding. When the FDA reviewed a compounding nomination for KPV in July 2026, it searched its own adverse-event database back to 2004 and found zero reports, in either direction. No side effects reported because essentially no human use has ever been monitored isn’t the same thing as a clean safety record, it’s an entirely separate category of risk.
Every claim above, traced back.
A 2026 peer-reviewed meta-analysis and two FDA regulatory documents. Click through and check them yourself.
Side-effect questions, answered.
It depends heavily on the mechanism class. GLP-1 and amylin-class peptides most commonly report gastrointestinal effects, nausea, diarrhoea, and constipation, in the 40-80% range across trials, alongside a quantified, elevated risk of injection-site reactions. GH-releasing peptides more often report flushing, injection-site irritation, and in some cases cardiovascular signals. There's no single "peptide side effect profile" that applies across every compound.
Usually not seriously, but they're real and quantified, not vendor speculation. A 2026 meta-analysis of 14 randomized trials (4,861 patients) found GLP-1 receptor agonists carried more than triple the injection-site-reaction risk of comparators (risk ratio 3.55). A retrospective analysis of FDA adverse-event data in the same study flagged exenatide and dulaglutide specifically for injection-site haemorrhage. Most reactions were mild, but a meaningful share of patients discontinued treatment over them.
GH-releasing peptides have the clearest documented signal in this category. CJC-1295's only large human trial was halted after a participant died of a heart attack. GHRP-2's FDA bulk-substances review separately notes a finding of death among critically ill study subjects, while explicitly caveating that causality was not established. Both are documented, real findings, covered in full on each compound's own evidence report.
Yes, and it's a structural risk that applies more broadly than any one compound's own trial data. The FDA's own guidance on immunogenicity assessment for therapeutic proteins explicitly extends its principles to peptides, and identifies product aggregates and manufacturing impurities, exactly the kind of quality control an unregulated research vial has no requirement to meet, as a recognized driver of unwanted immune responses.
More than people expect. When the FDA reviewed a compounding nomination for KPV in July 2026, it searched its own adverse-event database back to 2004 and found zero reports, in either direction. That's its own category of risk, not an absence of one: no side effects reported because essentially no human use has ever been monitored.
Keep researching.
A category-wide list can't tell you what a specific compound actually does.
Create your account to check any peptide's own documented side-effect data before it goes anywhere near your body.